A pharmaceutical composition comprising at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof, a glucomannan, a first polyalkylene oxide having an average molecular weight of no more than 300, 000, and a second polyalkylene oxide having an average molecular weight of at least 1, 000, 000 and methods of making. The pharmaceutical composition provides extended release of the API and has abuse deterrent features.